PHF6 mutations in chronic myelomonocytic leukemia identify a unique subset of patients with distinct phenotype and superior prognosis
American Journal of Hematology · 2024-12 · 99 (12) · 2321-2327
DOI: 10.1002/ajh.27492 ↗Kurz gefasst
Fachartikel in der Zeitschrift American Journal of Hematology, online erschienen am 27.09.2024. Verfasst von Ayalew Tefferi und 16 weiteren Autor:innen. Beteiligte Einrichtung: Division of Hematology, Mayo Clinic, Rochester, Minnesota, USA. Hauptthemen laut MEDLINE: Mutation, Leukemia, Myelomonocytic, Chronic, Repressor Proteins, Phenotype. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
The current study was inspired by observations from exploratory analyses of an institutional cohort with chronic myelomonocytic leukemia (CMML; N = 398) that revealed no instances of blast transformation in the seven patients with plant homeodomain finger protein 6 ( PHF6 ) mutation ( PHF6 MUT ). A subsequent Mayo Clinic enterprise‐wide database search identified 28 more cases with PHF6 MUT . Compared with their wild‐type PHF6 counterparts ( PHF6 WT ; N = 391), PHF6 MUT cases ( N = 35) were more likely to co‐express TET2 (89% vs. 45%; p < .01), RUNX1 (29% vs. 14%; p = .03), CBL (14% vs. 2%; p < .01), and U2AF1 (17% vs. 6%; p = .04) and less likely SRSF2 (23% vs. 45%; p < .01) mutation. They were also more likely to display loss of Y chromosome (LoY; 21% vs. 2%; p < .01) and platelets
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Division of Hematology, Mayo Clinic, Rochester, Minnesota, USA.
- Department of Laboratory Medicine, Mayo Clinic, Rochester, Minnesota, USA.
ORCID-Profile: Ayalew Tefferi, Anuya Natu, Abhishek A Mangaonkar, Aref Al-Kali, Animesh Pardanani, Rong He, Naseema Gangat, Mrinal M Patnaik
Zitieren
APA
Tefferi, A., Fathima, S., Alsugair, A. K. A., Aperna, F., Natu, A., Abdelmagid, M. G., Csizmar, C. M., Gurney, M., Lasho, T. L., Finke, C. M., Mangaonkar, A. A., Al-Kali, A., Pardanani, A., Reichard, K. K., He, R., Gangat, N., & Patnaik, M. M. (2024). PHF6 mutations in chronic myelomonocytic leukemia identify a unique subset of patients with distinct phenotype and superior prognosis. American Journal of Hematology, 99(12), 2321-2327. https://doi.org/10.1002/ajh.27492
Vancouver
Tefferi A, Fathima S, Alsugair AKA, Aperna F, Natu A, Abdelmagid MG, et al. PHF6 mutations in chronic myelomonocytic leukemia identify a unique subset of patients with distinct phenotype and superior prognosis. American Journal of Hematology. 2024;99(12):2321-2327. doi:10.1002/ajh.27492
BibTeX
@article{Tefferi2024,
author = {Tefferi, Ayalew and Fathima, Saubia and Alsugair, Ali Khalid A and Aperna, Fnu and Natu, Anuya and Abdelmagid, Maymona G and Csizmar, Clifford M and Gurney, Mark and Lasho, Terra L and Finke, Christy M and Mangaonkar, Abhishek A and Al-Kali, Aref and Pardanani, Animesh and Reichard, Kaaren K and He, Rong and Gangat, Naseema and Patnaik, Mrinal M},
title = {PHF6 mutations in chronic myelomonocytic leukemia identify a unique subset of patients with distinct phenotype and superior prognosis},
journal = {American Journal of Hematology},
year = {2024},
volume = {99},
number = {12},
pages = {2321--2327},
doi = {10.1002/ajh.27492}
}
EUVIMED